Browse Studies — Arctuva

Phase 1

A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti…

Metastatic Microsatellite Stable Colorectal Carcinoma

Estimated

~$10 – $7,500

Dan FengNCT07281716

Phase 1

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients wit…

Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more

Estimated

~$10 – $8,750

Nurix Therapeutics, Inc.

Phase 1

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more

Estimated

~$10 – $8,750

KaliVir ImmunotherapeuticsNCT06444815